600056.SH
中国医药
SSE · Healthcare · Medical - Distribution · CN
CNY 9.17
−0.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 35.0B | 35.4B | 35.2B | 38.8B | 37.6B |
| Cost of Revenue | 31.3B | 31.6B | 31.5B | 34.4B | 32.8B |
| Gross Profit | 3.7B | 3.7B | 3.8B | 4.4B | 4.7B |
| Operating Expenses | |||||
| R&D Expense | 159.4M | 158.4M | 125.2M | 115.5M | 77.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.1B | 1.1B | 1.0B | 1.1B | 1.0B |
| Selling & Marketing Expense | 965.9M | 1.0B | 1.1B | 1.6B | 2.0B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.4B | 2.5B | 2.6B | 3.1B | 3.3B |
| Cost and Expenses | 33.8B | 34.1B | 34.0B | 37.5B | 36.1B |
| Operating Income (EBIT) | 1.0B | 1.0B | 986.6M | 1.7B | 1.2B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.0B | 999.3M | 1.0B | 1.6B | 1.2B |
| Income Tax Expense | 322.4M | 324.7M | 274.3M | 398.4M | 307.7M |
| Bottom Line | |||||
| Net Income | 482.9M | 473.2M | 582.6M | 1.0B | 735.6M |
| Earnings from Cont. Ops | 678.3M | 674.6M | 733.8M | 1.2B | 888.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 482.9M | 473.2M | 582.6M | 1.0B | 735.6M |
| Per Share | |||||
| Basic EPS | CN¥0.32 | CN¥0.32 | CN¥0.39 | CN¥0.70 | CN¥0.49 |
| Diluted EPS | CN¥0.32 | CN¥0.32 | CN¥0.39 | CN¥0.70 | CN¥0.49 |
| Revenue Per Share | CN¥23.41 | CN¥23.64 | CN¥23.56 | CN¥25.95 | CN¥25.13 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | — | 1.4B | 1.4B | 2.0B | 1.5B |
| D&A | — | 410.8M | 389.8M | 354.5M | 333.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026